Get started
Author

Eduardo Bravo

Observed name: E. Bravo
ORCID: 0009-0006-8560-287X
Observed ORCID: 0009-0006-8560-287X
OpenAlex ID: A5082874248
Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy
2025 · Samantha Sekeres, Erica N. Lamkin, et al. · Genes · 4
PDF
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
2026 · Quinlan Sievers, Hao Lu, et al. · Cancer Discovery · 3
Therapeutic potential of STK17A targeted therapies
2025 · Hafsa Ouaakki, Eduardo Bravo, et al. · Bioorganic & Medicinal Chemistry Letters · 2
Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation
2025 · Quinlan Sievers, Hao Lu, et al. · Blood · 2
PDF
Abstract A025: CFON-026, a novel macrocyclic BTK inhibitor disrupts scaffold-dependent signaling and overcomes resistance to BTK-directed therapies
2026 · Erica N. Lamkin, Tim Kong, et al. · Blood Cancer Discovery · 1
Remibrutinib (Rhapsido) for chronic spontaneous urticaria
2026 · Erica N. Lamkin, Eduardo Bravo, et al. · Trends in Pharmacological Sciences · 1
Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies
2026 · Eduardo Bravo, Claudia Cabrera Pastrana, et al. · Cells
Abstract B085: Selective oral STK17A inhibitor UMF814A targets a previously unrecognized dark kinase vulnerability in spliceosome-mutant MDS and AML
2026 · Eric Spinetti, Claudia C. Pastrana, et al. · Clinical Cancer Research
Abstract PR002: Dark kinase dependency screening reveals STK17A as a previously unrecognized targetable vulnerability in EGFR-altered glioblastoma
2026 · Eric Spinetti, Christian K. Ramsoomair, et al. · Clinical Cancer Research
Abstract B084: Dark kinase dependency screening reveals STK17A as a previously unrecognized targetable vulnerability in EGFR-altered glioblastoma
2026 · Eric Spinetti, Christian K. Ramsoomair, et al. · Clinical Cancer Research
Abstract PR004: BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials
2026 · Quinlan Sievers, Hao Lu, et al. · Blood Cancer Discovery
Abstract 7069: Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged acute myeloid leukemia.
2026 · Tulasigeri Totiger, Mina Tayari, et al. · Cancer Research
Therapeutic Potential of STK17A Targeted Therapies
2025 · Yangbo Feng, Hafsa Ouaakki, et al. · SSRN Electronic Journal
Works count: 14
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type